Advertisement

Cancer Immunology, Immunotherapy

, Volume 54, Issue 1, pp 67–77 | Cite as

Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells

  • Katharina Gabriele Hüttner
  • Sabine Konstanze Breuer
  • Petra Paul
  • Otto Majdic
  • Andreas Heitger
  • Thomas Felzmann
Original Article

Abstract

To induce cytolytic immunity, dendritic cells (DCs) need to release bioactive interleukin-12 (IL-12) p70 heterodimeric molecules. To study the role of IL-12 for the generation of an anti-tumor immune response, we generated two classes of DCs. (1) DCs were initiated to secrete IL-12 by exposure to LPS/IFN-γ for 2 h resulting, as demonstrated in vitro, in continued IL-12 release for another 24 h (termed active DCs). (2) DCs were exposed to LPS/IFN-γ for 24 h and injected into mice at a time point when IL-12 production had ceased (termed exhausted DCs). These two classes of DCs were probed for their capacity to induce a cytolytic anti-tumor immune response in vivo in a syngeneic mouse tumor model. The mouse tumor cell line K-Balb was engineered to express neomycin phosphotransferase (NPT) as a model tumor antigen. DCs were charged with various NPT-derived antigens, including recombinant NPT protein, whole tumor cell lysate and NPT-derived synthetic peptides, and the induction of in vivo anti-tumor immunity was determined by measuring tumor growth. Only the injection of active DCs, i.e., cells that maintained the capacity to secrete IL-12, but not exhausted DCs that had lost the ability to produce IL-12, resulted in a measurable deceleration of growth of K-Balb-NPT tumors. This anti-tumor immune response was most pronounced when using recombinant protein as an antigen source, which was evident in a prophylactic as well as in a therapeutic setting. The absence of a response to parental K-Balb tumors confirmed the antigen specificity of the anti-tumor immune response. Together these data provide evidence for the unique capacity of actively IL-12 secreting DCs to trigger effective anti-tumor immunity using exogenous tumor antigens.

Keywords

Antigen presenting cell (APC) Dendritic cell (DC) Interleukin-12 (IL-12) Cytotoxic T lymphocyte (CTL) Cytolytic anti-tumor immune response 

Notes

Acknowledgements

The work of the authors is supported by numerous private donations to the Children’s Cancer Research Institute that partly funded this study and by grants from the Austrian Industrial Research Promotion Fund (Forschungsförderungsfond der Gewerblichen Wirtschaft, Projektnummer 804445), the Vienna Business Agency (Wiener Wirtschaftsförderungsfond) and the Austrian National Bank (Jubiläumsfond der Österreichischen Nationalbank, Projektnummer 7774). We thank Eva Schmitt for excellent technical assistance and Peter Kinross for carefully reading the manuscript.

References

  1. 1.
    Aliberti J, Schulz O, Pennington DJ, Tsujimura H, Reis e Sousa C, Ozato K, Sher A (2003) Essential role for ICSBP in the in vivo development of murine CD8alpha + dendritic cells. Blood 101:305CrossRefPubMedGoogle Scholar
  2. 2.
    Camporeale A, Boni A, Iezzi G, Degl’Innocenti E, Grioni M, Mondino A, Bellone M (2003) Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res 63:3688PubMedGoogle Scholar
  3. 3.
    Carbone FR, Bevan MJ (1990) Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 171:377CrossRefPubMedGoogle Scholar
  4. 4.
    Danner R, Joiner K, Rubin M, Patterson W, Johnson N, Ayers K, Parrillo J (1989) Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob Agents Chemother 33:1428PubMedGoogle Scholar
  5. 5.
    delHoyo GM, Martin P, Vargas HH, Ruiz S, Arias CF, Ardavin C (2002) Characterization of a common precursor population for dendritic cells. Nature 425:1043CrossRefGoogle Scholar
  6. 6.
    Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells. J Exp Med 193:233CrossRefPubMedGoogle Scholar
  7. 7.
    Donovan J, Brown P (1995) Euthanasia. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W (eds) Current protocols in immunology, vol 1. Wiley, New YorkGoogle Scholar
  8. 8.
    Felzmann T, Buchberger M, Jechlinger M, Kircheis R, Wagner E, Gadner H (2000) Xenogenization by tetanus toxoid loading into lymphoblastoid cell lines and primary human tumor cells mediated by polycations and liposomes. Cancer Lett 161:241CrossRefPubMedGoogle Scholar
  9. 9.
    Ferlazzo G, Semino C, Spaggiari GM, Meta M, Mingari MC, Melioli G (2000) Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates. Int Immunol 12:1741CrossRefPubMedGoogle Scholar
  10. 10.
    Gallucci S, Lolkema M, Matzinger P (1999) Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5:1249CrossRefPubMedGoogle Scholar
  11. 11.
    Graner MW, Zeng Y, Feng H, Katsanis E (2003) Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother 52:226PubMedGoogle Scholar
  12. 12.
    Guerriero A, Langmuir PB, Spain LM, Scott EW (2000) PU.1 is required for myeloid-derived but not lymphoid-derived dendritic cells. Blood 95:879PubMedGoogle Scholar
  13. 13.
    Gunzer M, Janich S, Varga G, Grabbe S (2001) Dendritic cells and tumor immunity. Semin Immunol 13:291CrossRefPubMedGoogle Scholar
  14. 14.
    Hart DN (1997) Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90:3245PubMedGoogle Scholar
  15. 15.
    Hilkens CM, Kalinski P, deBoer M, Kapsenberg ML (1997) Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 90:1920PubMedGoogle Scholar
  16. 16.
    Hochrein H, O’Keeffe M, Luft T, Vandenabeele S, Grumont RJ, Maraskovsky E, Shortman K (2000) Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med 192:823CrossRefPubMedGoogle Scholar
  17. 17.
    Langenkamp A, Messi M, Lanzavecchia A, Sallusto F (2000) Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 1:3116CrossRefGoogle Scholar
  18. 18.
    Lanzavecchia A, Sallusto F (2001) Regulation of T cell immunity by dendritic cells. Cell 106:263CrossRefPubMedGoogle Scholar
  19. 19.
    Ludewig B, McCoy K, Pericin M, Ochsenbein AF, Dumrese T, Odermatt B, Toes REM, Melief CJM, Hengartner H, Zinkernagel RM (2001) Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol 166:3678PubMedGoogle Scholar
  20. 20.
    Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, Wysocka M, Trinchieri G, Murphy KM, O’Garra A (1995) Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 154:5071PubMedGoogle Scholar
  21. 21.
    Manz MG, Traver D, Miyamoto T, Weissman IL, Akashi K (2001) Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood 97:3333CrossRefPubMedGoogle Scholar
  22. 22.
    Martin P, del Hoyo GM, Anjuere F, Ruiz SR, Arias CF, Marin AR, Ardavin C (2000) Concept of lymphoid versus myeloid dendritic cell lineages revisited: both CD8alpha(-) and CD8alpha(+) dendritic cells are generated from CD4(low) lymphoid-committed precursors. Blood 96:2511PubMedGoogle Scholar
  23. 23.
    Mazzaccaro RJ, Gedde M, Jensen ER, van Santen HM, Ploegh HL, Rock KL, Bloom BR (1996) Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 93:11786CrossRefPubMedGoogle Scholar
  24. 24.
    Moser M, Murphy KM (2000) Dendritic cell regulation of TH1-TH2 development. Nat Immunol 1:199CrossRefPubMedGoogle Scholar
  25. 25.
    Naik S, Vremec D, Wu L, O’Keeffe M, Shortman K (2003) CD8alpha+ mouse spleen dendritic cells do not originate from the CD8alpha-dendritic cell subset. Blood 102:601CrossRefPubMedGoogle Scholar
  26. 26.
    Nishimura A, Morita M, Nishimura Y, Sugino Y (1990) A rapid and highly efficient method for preparation of competent Escherichia coli cells. Nucleic Acids Res 18:6169PubMedGoogle Scholar
  27. 27.
    Ridge JP, Di-Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474CrossRefPubMedGoogle Scholar
  28. 28.
    Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109CrossRefPubMedGoogle Scholar
  29. 29.
    Schoenberger SP, Toes RE, van-der-Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480CrossRefPubMedGoogle Scholar
  30. 30.
    Simmons CP, Mastroeni P, Fowler R, Ghaem-maghami M, Lycke N, Pizza M, Rappuoli R, Dougan G (1999) MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J Immunol 163:6502PubMedGoogle Scholar
  31. 31.
    Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML (1998) High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 10:1593CrossRefPubMedGoogle Scholar
  32. 32.
    Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N (2001) Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 61:7563PubMedGoogle Scholar
  33. 33.
    Toes RE, Ossendorp F, Offringa R, Melief CJ (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189:753CrossRefPubMedGoogle Scholar
  34. 34.
    Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133CrossRefPubMedGoogle Scholar
  35. 35.
    Vegh Z, Mazumder A (2003) Generation of tumor cell lysate-loaded dendritic cells preprogrammed for IL-12 production and augmented T cell response. Cancer Immunol Immunother 52:67PubMedGoogle Scholar
  36. 36.
    Wang P, Vanky F, Vegh Z, Persson U, Hising C, Klein E (1992) Assembly of MHC class I molecules in ex vivo carcinoma cells induced by IFN-gamma or by a binding peptide. Cell Immunol 142:296PubMedGoogle Scholar
  37. 37.
    Whiteside T, Odoux C (2004) Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 53:240CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Katharina Gabriele Hüttner
    • 1
  • Sabine Konstanze Breuer
    • 1
  • Petra Paul
    • 1
  • Otto Majdic
    • 2
  • Andreas Heitger
    • 1
  • Thomas Felzmann
    • 1
  1. 1.Children’s Cancer Research InstituteSt. Anna Children’s HospitalViennaAustria
  2. 2.Institute of ImmunologyMedical University of ViennaViennaAustria

Personalised recommendations